Misleading guidance from pharmacogenomic testing

American Journal of Psychiatry

Volumn 174, Issue 10, 2017, Pages 922-924

  Rahman, Tahir ^a   Ash, David M ^a   Lauriello, John ^a   Rawlani, Roshni ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOZAPINE; HALOPERIDOL; HALOPERIDOL DECANOATE; LITHIUM; LONG ACTING DRUG; OLANZAPINE; PALIPERIDONE; VALPROIC ACID; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGGRESSION; AGITATION; AUDITORY HALLUCINATION; AUTOMUTILATION; BEHAVIOR; CASE REPORT; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CONFERENCE PAPER; DELUSION; DISEASE EXACERBATION; DISTRESS SYNDROME; DRUG RESPONSE; EVIDENCE BASED PRACTICE; FAMILY HISTORY; HETEROZYGOTE; HUMAN; MALE; MEDICATION THERAPY MANAGEMENT; MENTAL HEALTH; NEUTROPENIA; PATIENT CARE; PHARMACOGENETIC TESTING; PRIORITY JOURNAL; RECURRENT DISEASE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SPEECH; TREATMENT OUTCOME; GENETICS; PHARMACOGENETICS; PROCEDURES;

ADULT; ANTIPSYCHOTIC AGENTS; CLINICAL DECISION-MAKING; CLOZAPINE; HUMANS; MALE; PHARMACOGENETICS; PHARMACOGENOMIC TESTING; SCHIZOPHRENIA;

EID: 85031321205     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2017.16121353     Document Type: Conference Paper

References (14)

1. Silverstone PH: Prevention of clozapine-induced neutropenia by pretreatment with lithium. J Clin Psychopharmacol 1998; 18: 86-88
2. Kohlrausch FB: Pharmacogenetics in schizophrenia: a review of clozapine studies. Rev Bras Psiquiatr 2013; 35:305-317
3. Basile VS, Masellis M, Potkin SG, et al: Pharmacogenomics in schizophrenia: the quest for individualized therapy.HumMolGenet 2002; 11:2517-2530
4. Masellis M, Basile VS, Özdemir V, et al: Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biol Psychiatry 2000; 47:252-266
5. Eum S, Lee AM, Bishop JR: Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues Clin Neurosci 2016; 18:323-337
6. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
7. Zhang J-P, Malhotra AK: Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011; 7:9-37
8. Arinami T, Gao M, Hamaguchi H, et al: Afunctional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6:577-582
9. Lencz T, Robinson DG, Xu K, et al: DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication infirstepisode schizophrenia patients. Am J Psychiatry 2006; 163:529-531
10. Vance GH, Barry TS, Bloom KJ, et al: Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 2009; 133:611-612
11. Drake RE, Goldman HH, Leff HS, et al: Implementing evidencebased practices in routine mental health service settings. Psychiatr Serv 2001; 52:179-182
12. Jerrell JM, Ridgely MS: Impact of robustness of program implementation on outcomes of clients in dual diagnosis programs. Psychiatr Serv 1999; 50:109-112
13. McDonnell J, Nofs D, HardmanM, et al: An analysis of the procedural components of supported employment programs associated with employment outcomes. J Appl Behav Anal 1989; 22:417-428
14. McHugo GJ, Drake RE, Teague GB, et al: Fidelity to assertive community treatment and client outcomes in the New Hampshire dual disorders study. Psychiatr Serv 1999; 50:818-824